{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:10:01Z","timestamp":1792195801615,"version":"4.4.0"},"reference-count":21,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:p>Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate. Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech development, recurrent seizures, behavior problems, and involuntary movements. The birth prevalence of GAMT deficiency is likely between 0.5 and 2 per million live births. On the basis of small case series and sibling data, presymptomatic treatment with oral supplements of creatine, ornithine, and sodium benzoate, and a protein-restricted diet to reduce arginine intake, appear to substantially improve health and developmental outcomes. Without newborn screening, diagnosis typically happens after the development of significant impairment, when treatment has limited utility. GAMT deficiency newborn screening can be incorporated into the tandem-mass spectrometry screening that is already routinely used for newborn screening, with about 1 per 100\u2009000 newborns screening positive. After a positive screen, diagnosis is established by finding an elevated guanidinoacetate concentration and low creatine concentration in the blood. Although GAMT deficiency is significantly more rare than other conditions included in newborn screening, the feasibility of screening, the low number of positive results, the relative ease of diagnosis, and the expected benefit of presymptomatic dietary therapy led to a recommendation from the Advisory Committee on Heritable Disorders in Newborns and Children to the Secretary of Health and Human Services that GAMT deficiency be added to the Recommended Uniform Screening Panel. This recommendation was accepted in January 2023.<\/jats:p>","DOI":"10.1542\/peds.2023-062100","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T08:43:03Z","timestamp":1689756183000},"source":"Crossref","is-referenced-by-count":15,"title":["Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening"],"prefix":"10.1542","volume":"152","author":[{"given":"Margie A.","family":"Ream","sequence":"first","affiliation":[{"name":"aDivision of Child Neurology, Nationwide Children's Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy K.K.","family":"Lam","sequence":"additional","affiliation":[{"name":"bDuke Clinical and Translational Science Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Grosse","sequence":"additional","affiliation":[{"name":"cNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelili","family":"Ojodu","sequence":"additional","affiliation":[{"name":"dAssociation of Public Health Laboratories, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Jones","sequence":"additional","affiliation":[{"name":"dAssociation of Public Health Laboratories, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Prosser","sequence":"additional","affiliation":[{"name":"eSusan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Rose","sequence":"additional","affiliation":[{"name":"eSusan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Comeau","sequence":"additional","affiliation":[{"name":"fNew England Newborn Screening Program, Department of Pediatrics, UMass Chan School of Medicine, Worcester, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tanksley","sequence":"additional","affiliation":[{"name":"gTexas Department of State Health Services, Laboratory Services Section, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Powell","sequence":"additional","affiliation":[{"name":"hDivision of Genetics and Metabolism, Department of Pediatrics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Kemper","sequence":"additional","affiliation":[{"name":"iDivision of Primary Care Pediatrics, Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"issue":"2","key":"2023111414363572500_B1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/gim.2013.98","article-title":"Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary\u2019s Advisory Committee on Heritable Disorders in Newborns and Children","volume":"16","author":"Kemper","year":"2014","journal-title":"Genet Med"},{"key":"2023111414363572500_B2","unstructured":"Mercimek-Andrews\u2008S, Salomons\u2008GS. University of Washington. Creatine deficiency disorders. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK3794\/. Accessed February 19, 2023"},{"issue":"3","key":"2023111414363572500_B3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejpn.2018.02.007","article-title":"Treatment outcome of twenty-two patients with guanidinoacetate methyltransferase deficiency: an international retrospective cohort study","volume":"22","author":"Khaikin","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"2023111414363572500_B4","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/humu.22511","article-title":"Thirteen new patients with guanidinoacetate methyltransferase deficiency and functional characterization of nineteen novel missense variants in the GAMT gene","volume":"35","author":"Mercimek-Mahmutoglu","year":"2014","journal-title":"Hum Mutat"},{"issue":"3","key":"2023111414363572500_B5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/01.wnl.0000234852.43688.bf","article-title":"GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis","volume":"67","author":"Mercimek-Mahmutoglu","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"2023111414363572500_B6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ymgme.2008.10.008","article-title":"Expanded clinical and molecular spectrum of guanidinoacetate methyltransferase (GAMT) deficiency","volume":"96","author":"Dhar","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2023111414363572500_B7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ymgme.2013.10.018","article-title":"Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring","volume":"111","author":"Stockler-Ipsiroglu","year":"2014","journal-title":"Mol Genet Metab"},{"key":"2023111414363572500_B8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.placenta.2017.02.020","article-title":"Creatine biosynthesis and transport by the term human placenta","volume":"52","author":"Ellery","year":"2017","journal-title":"Placenta"},{"issue":"6","key":"2023111414363572500_B9","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00438-015-1067-x","article-title":"Carrier frequency of guanidinoacetate methyltransferase deficiency in the general population by functional characterization of missense variants in the GAMT gene","volume":"290","author":"Desroches","year":"2015","journal-title":"Mol Genet Genomics"},{"issue":"1","key":"2023111414363572500_B10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.gene.2015.08.045","article-title":"A pilot study to estimate incidence of guanidinoacetate methyltransferase deficiency in newborns by direct sequencing of the GAMT gene","volume":"575","author":"Mercimek-Mahmutoglu","year":"2016","journal-title":"Gene"},{"issue":"3","key":"2023111414363572500_B11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2013.08.020","article-title":"Evidence-based treatment of guanidinoacetate methyltransferase (GAMT) deficiency","volume":"110","author":"Viau","year":"2013","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2023111414363572500_B12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10545-013-9662-7","article-title":"Feasibility of newborn screening for guanidinoacetate methyltransferase (GAMT) deficiency","volume":"37","author":"Pasquali","year":"2014","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"2023111414363572500_B13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2014.01.005","article-title":"Newborn screening for guanidinoacetate methyl transferase deficiency","volume":"111","author":"Pitt","year":"2014","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2023111414363572500_B14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ymgme.2016.05.002","article-title":"A three-tier algorithm for guanidinoacetate methyltransferase (GAMT) deficiency newborn screening","volume":"118","author":"Sinclair","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"1-2","key":"2023111414363572500_B15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymgme.2021.07.012","article-title":"Prospective identification by neonatal screening of patients with guanidinoacetate methyltransferase deficiency","volume":"134","author":"Hart","year":"2021","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2023111414363572500_B16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ymgme.2022.01.101","article-title":"Method modification to reduce false positives for newborn screening of guanidinoacetate methyltransferase deficiency","volume":"135","author":"Wojcik","year":"2022","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2023111414363572500_B17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymgme.2013.03.003","article-title":"Elevation of guanidinoacetate in newborn dried blood spots and impact of early treatment in GAMT deficiency","volume":"109","author":"El-Gharbawy","year":"2013","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2023111414363572500_B18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1212\/01.wnl.0000230152.25203.01","article-title":"Presymptomatic treatment of neonatal guanidinoacetate methyltransferase deficiency","volume":"67","author":"Schulze","year":"2006","journal-title":"Neurology"},{"key":"2023111414363572500_B19","first-page":"S125","article-title":"Creatine deficiency syndrome: case report","volume":"34","author":"Farshidi","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"2023111414363572500_B20","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-40337-8_32","article-title":"Chapter 24: disorders of creatine metabolism","volume-title":"Physician\u2019s Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases","author":"St\u00f6ckler-Ipsiroglu","year":"2014","edition":"2nd ed."},{"issue":"36","key":"2023111414363572500_B21","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15585\/mmwr.mm6936a6","article-title":"Infants with congenital disorders identified through newborn screening\u2013United States, 2015\u20132017","volume":"69","author":"Sontag","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2023-062100\/1566960\/peds_2023062100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2023-062100\/1566960\/peds_2023062100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T14:38:27Z","timestamp":1699972707000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/152\/2\/e2023062100\/192800\/Evidence-and-Recommendation-for-Guanidinoacetate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,7,19]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2023-062100","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"article-number":"e2023062100"}}